New Concepts on Pathogenesis and Diagnosis of Liver Fibrosis; A Review Article
- PMID: 27698966
- PMCID: PMC5045669
- DOI: 10.15171/mejdd.2016.29
New Concepts on Pathogenesis and Diagnosis of Liver Fibrosis; A Review Article
Abstract
Liver fibrosis is a potentially reversible response to hepatic insults, triggered by different chronic diseases most importantly viral hepatitis, alcoholic, and nonalcoholic fatty liver disease. In the course of the chronic liver disease, hepatic fibrogenesis may develop, which is attributed to various types of cells, molecules, and pathways. Activated hepatic stellate cell (HSC), the primary source of extracellular matrix (ECM), is fundamental in pathophysiology of fibrogenesis, and thus is the most attractable target for reversing liver fibrosis. Although, liver biopsy has long been considered as the gold standard for diagnosis and staging of hepatic fibrosis, assessing progression and regression by biopsy is hampered by its limitations. We provide recent views on noninvasive approaches including serum biomarkers and radiologic techniques.
Keywords: Diagnosis; Fibrosis; Genetic Therapy; Liver Cirrhosis; Pathogenesis; Therapeutics.
Similar articles
-
Non-invasive diagnosis of advanced fibrosis and cirrhosis.World J Gastroenterol. 2014 Dec 7;20(45):16820-30. doi: 10.3748/wjg.v20.i45.16820. World J Gastroenterol. 2014. PMID: 25492996 Free PMC article. Review.
-
Liver fibrosis: Direct antifibrotic agents and targeted therapies.Matrix Biol. 2018 Aug;68-69:435-451. doi: 10.1016/j.matbio.2018.04.006. Epub 2018 Apr 12. Matrix Biol. 2018. PMID: 29656147 Review.
-
Tetramethylpyrazine reduces glucose and insulin-induced activation of hepatic stellate cells by inhibiting insulin receptor-mediated PI3K/AKT and ERK pathways.Mol Cell Endocrinol. 2014 Jan 25;382(1):197-204. doi: 10.1016/j.mce.2013.09.020. Epub 2013 Sep 24. Mol Cell Endocrinol. 2014. PMID: 24071517
-
Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C.World J Gastroenterol. 2020 Jan 14;26(2):109-133. doi: 10.3748/wjg.v26.i2.109. World J Gastroenterol. 2020. PMID: 31969775 Free PMC article. Review.
-
Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease.Gastroenterology. 2016 Jun;150(8):1811-1822.e4. doi: 10.1053/j.gastro.2016.03.008. Epub 2016 Mar 19. Gastroenterology. 2016. PMID: 27003601
Cited by
-
Evolution of proteomic biomarker for chronic liver disease: Promise into reality.J Circ Biomark. 2018 May 22;7:1849454418777186. doi: 10.1177/1849454418777186. eCollection 2018 Jan-Dec. J Circ Biomark. 2018. PMID: 29854010 Free PMC article. Review.
-
Antiliver Fibrosis Screening of Active Ingredients from Apium graveolens L. Seeds via GC-TOF-MS and UHPLC-MS/MS.Evid Based Complement Alternat Med. 2020 Feb 18;2020:8321732. doi: 10.1155/2020/8321732. eCollection 2020. Evid Based Complement Alternat Med. 2020. PMID: 32148553 Free PMC article.
-
Liver fibrosis: a compilation on the biomarkers status and their significance during disease progression.Future Sci OA. 2017 Oct 5;4(1):FSO250. doi: 10.4155/fsoa-2017-0083. eCollection 2018 Jan. Future Sci OA. 2017. PMID: 29255622 Free PMC article. Review.
-
CD44 inhibits α-SMA gene expression via a novel G-actin/MRTF-mediated pathway that intersects with TGFβR/p38MAPK signaling in murine skin fibroblasts.J Biol Chem. 2019 Aug 23;294(34):12779-12794. doi: 10.1074/jbc.RA119.007834. Epub 2019 Jul 8. J Biol Chem. 2019. PMID: 31285260 Free PMC article.
-
New Concepts on Reversibility and Targeting of Liver Fibrosis; A Review Article.Middle East J Dig Dis. 2018 Jul;10(3):133-148. doi: 10.15171/mejdd.2018.103. Epub 2018 Jun 14. Middle East J Dig Dis. 2018. PMID: 30186577 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources